TY - JOUR
T1 - When mutants gain new powers
T2 - News from the mutant p53 field
AU - Brosh, Ran
AU - Rotter, Varda
N1 - Funding Information:
Supported by a Center of Excellence grant from the Flight Attendant Medical Research Institute (FAMRI). V.R. is the incumbent of the Norman and Helen Asher Professorial Chair for Cancer Research at the Weizmann institute.
PY - 2009/10
Y1 - 2009/10
N2 - Ample data indicate that mutant p53 proteins not only lose their tumour suppressive functions, but also gain new abilities that promote tumorigenesis. Moreover, recent studies have modified our view of mutant p53 proteins, portraying them not as inert mutants, but rather as regulated proteins that influence the cancer cell transcriptome and phenotype. This influence is clinically manifested as association of TP53 mutations with poor prognosis and drug resistance in a growing array of malignancies. Here, we review recent studies on mutant p53 regulation, gain-of-function mechanisms, transcriptional effects and prognostic association, with a focus on the clinical implications of these findings.
AB - Ample data indicate that mutant p53 proteins not only lose their tumour suppressive functions, but also gain new abilities that promote tumorigenesis. Moreover, recent studies have modified our view of mutant p53 proteins, portraying them not as inert mutants, but rather as regulated proteins that influence the cancer cell transcriptome and phenotype. This influence is clinically manifested as association of TP53 mutations with poor prognosis and drug resistance in a growing array of malignancies. Here, we review recent studies on mutant p53 regulation, gain-of-function mechanisms, transcriptional effects and prognostic association, with a focus on the clinical implications of these findings.
UR - http://www.scopus.com/inward/record.url?scp=70349443284&partnerID=8YFLogxK
U2 - 10.1038/nrc2693
DO - 10.1038/nrc2693
M3 - Review article
C2 - 19693097
AN - SCOPUS:70349443284
VL - 9
SP - 701
EP - 713
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
SN - 1474-175X
IS - 10
ER -